Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

BACKGROUND: Advanced biliary tract cancers (BTCs) have a poor prognosis and limited treatment options. This exploratory phase II study aimed to evaluate the activity of the mTOR inhibitor everolimus in advanced BTC and explore prognostic biomarkers. METHODS: Patients with advanced BTCs, who had not...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, David K., Tay, Rebecca Y., Yeung, Yvonne H., Chionh, Fiona, Mooi, Jennifer, Murone, Carmel, Skrinos, Effie, Price, Timothy J., Mariadason, John M., Tebbutt, Niall C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931084/
https://www.ncbi.nlm.nih.gov/pubmed/29527009
http://dx.doi.org/10.1038/s41416-018-0021-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931084/
https://www.ncbi.nlm.nih.gov/pubmed/29527009
http://dx.doi.org/10.1038/s41416-018-0021-1

Ejemplares similares